Cognition enhancing or neuroprotective compounds for the treatment of cognitive disorders: why? when? which?

Author： Lockhart B.P.   Lestage P.J.  

Publisher： Elsevier

ISSN： 0531-5565

Source： Experimental Gerontology, Vol.38, Iss.1, 2003-01, pp. : 119-128

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Modern Imaging Techniques: Which - When - Why?

By  

Digestive Diseases, Vol. 31, Iss. 1, 2013-06 ,pp. : 63-68

Karger

Access to resources Recommend Favorite

Understanding why cognitive-behavioral therapy is an effective treatment for adolescents with juvenile fibromyalgia

By Sil Soumitri   Kashikar-Zuck Susmita  

International Journal of Clinical Rheumatology, Vol. 8, Iss. 2, 2013-04 ,pp. : 213-219

Future Medicine

Access to resources Recommend Favorite

Probiotics: Which and When?

By  

Digestive Diseases, Vol. 26, Iss. 2, 2008-04 ,pp. : 175-182

Karger

Access to resources Recommend Favorite

Cognition-Enhancing Effects of Donepezil in Traumatic Brain Injury

By  

European Neurology, Vol. 54, Iss. 1, 2005-09 ,pp. : 39-45

Karger

Access to resources Recommend Favorite

Osteoarthritis of the hip or knee: which coexisting disorders are disabling?

By Reeuwijk Kerstin   Rooij Mariëtte   Dijk Gabriella   Veenhof Cindy   Steultjens Martijn   Dekker Joost  

Clinical Rheumatology, Vol. 29, Iss. 7, 2010-07 ,pp. : 739-747

Springer Publishing Company

Access to resources Recommend Favorite